KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 M{D0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle0TWM2OD1|LkK3N|UzKM7:TR?= M{XBfXNCVkeHUh?=
HuO-3N1 M2TXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[z[mlEPTB;ND6xO|E1OiEQvF2= MmLsV2FPT0WU
LAMA-84 NF7jUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHlXmdKSzVyPUSuOVg1PjVizszN MlfJV2FPT0WU
CAL-72 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTVwNEiwPFQh|ryP M{O5THNCVkeHUh?=
LoVo NFvtdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HCUGlEPTB;Nj65N|I{QSEQvF2= MYPTRW5ITVJ?
HH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X1XGlEPTB;OD6yO|Y4OSEQvF2= MnfrV2FPT0WU
SK-MEL-3 NXfiNmJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTxTWM2OD16LkK4OVc2KM7:TR?= NF3WeZNUSU6JRWK=
KM12 NGi4RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnHd2RiUUN3ME25MlIyOTR{IN88US=> MnLXV2FPT0WU
NCI-H1437 NWGyTnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPUeoRKUUN3ME25MlgxQTdizszN M3HNXnNCVkeHUh?=
NCI-H1838 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3VGlEPTB;MUGuNVg3PSEQvF2= NYjTOVRZW0GQR1XS
J-RT3-T3-5 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL0UFhWUUN3ME2xNU4zPDF5IN88US=> MlvmV2FPT0WU
GOTO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrjXGF2UUN3ME2xNU43QTl4IN88US=> NIDtdY9USU6JRWK=
LB2241-RCC M4excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFzLkexPFYh|ryP M2\tOHNCVkeHUh?=
ES7 M2PK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmyeopKSzVyPUGxMlc5QCEQvF2= NET0UVdUSU6JRWK=
KP-N-YS NUHGWFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF{Lk[zOVQh|ryP NIrKR4RUSU6JRWK=
CAL-12T MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF|Lk[xO{DPxE1? NGHoUIhUSU6JRWK=
COLO-684 M3fKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L5fmlEPTB;MUSuNVU3QSEQvF2= MXHTRW5ITVJ?
DOK NULydnhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nJXWlEPTB;MUWuN|MzQSEQvF2= NWjLUoFlW0GQR1XS
Hs-578-T NWnBflRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHNUY9KSzVyPUG1MlQyQDJizszN MmjTV2FPT0WU
D-423MG NULReGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\NTWM2OD1zNT61NlM3KM7:TR?= NHzzcG5USU6JRWK=
DBTRG-05MG MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:ybmRKSzVyPUG1MlYyOTFizszN MknDV2FPT0WU
VM-CUB-1 NHP4RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD1zNT65PFQ6KM7:TR?= MmjDV2FPT0WU
KG-1 NX\G[HlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC4TWM2OD1zNj6wPVk3KM7:TR?= Ml3vV2FPT0WU
8305C NWiyN|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjKVIlKSzVyPUG2MlE5QDlizszN NUTFZoJ[W0GQR1XS
HuH-7 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF4LkK2O|Qh|ryP NHzEVHhUSU6JRWK=
LXF-289 NF;YW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HFRWlEPTB;MU[uNlc1PyEQvF2= NFj4fHRUSU6JRWK=
NCI-H1793 M2rucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF4LkS3NVIh|ryP MYHTRW5ITVJ?
ChaGo-K-1 NFTKVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF4Lk[1Olgh|ryP M3vVZ3NCVkeHUh?=
GCIY NIPFTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmThTWM2OD1zNj63PVA2KM7:TR?= NUfHd|ZzW0GQR1XS
SK-MEL-28 NIj5dItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF5LkC0O|Uh|ryP MnvvV2FPT0WU
NCI-SNU-1 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF5LkGyOlkh|ryP M4DubHNCVkeHUh?=
CTB-1 NYrOdpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF5LkKyOVkh|ryP NUnCe3FuW0GQR1XS
NCI-H82 M3y3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF5LkS1O|Mh|ryP NWDBWItRW0GQR1XS
HCC2998 M1zqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmwcYdKSzVyPUG3MlY4OzNizszN NHPxW5ZUSU6JRWK=
NCI-H2030 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuTXBCUUN3ME2xPE4yQTl5IN88US=> NF3ySnlUSU6JRWK=
HuP-T3 NGHCSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTEWnlHUUN3ME2xPE42QDh6IN88US=> MUHTRW5ITVJ?
697 NUTJRlVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S3UWlEPTB;MUmuNFIxOSEQvF2= NF;mNYNUSU6JRWK=
MLMA NIHqWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjmTWM2OD1zOT6wOVU4KM7:TR?= NHHPN5JUSU6JRWK=
HCC70 NGKwN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF7LkS4PUDPxE1? NH;veYRUSU6JRWK=
A704 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqNVhoUUN3ME2xPU45OzB3IN88US=> MVPTRW5ITVJ?
D-283MED M1TH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HzWGlEPTB;MkCuOVM{QSEQvF2= MWrTRW5ITVJ?
U031 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGxXpdKSzVyPUKxMlE1QDlizszN MnjTV2FPT0WU
HSC-3 M1rIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq0R4lKSzVyPUKxMlE5OzVizszN NUTQVY5vW0GQR1XS
JVM-3 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELLUGRKSzVyPUKyMlUxPiEQvF2= NWjpbHR5W0GQR1XS
Mewo NF3VcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHxXXNKSzVyPUKyMlUxPzNizszN MY\TRW5ITVJ?
YH-13 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTuTWM2OD1{Mj61NVI{KM7:TR?= MYPTRW5ITVJ?
LB1047-RCC Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID2OJlKSzVyPUKyMlU5PzlizszN M3THVHNCVkeHUh?=
HCC2157 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXvSohTUUN3ME2yNk45ODV2IN88US=> MWfTRW5ITVJ?
SNU-449 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ{Lki3OFgh|ryP MXPTRW5ITVJ?
Ramos-2G6-4C10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnZTWM2OD1{Mj65OkDPxE1? MYDTRW5ITVJ?
CHL-1 M2LXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojLTWM2OD1{Mz63NlkzKM7:TR?= M2PzR3NCVkeHUh?=
SK-MEL-30 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPEXllKSzVyPUK0MlQ3PjJizszN MXrTRW5ITVJ?
PANC-08-13 NGDweIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqxPYZKSzVyPUK1MlA6OzhizszN MULTRW5ITVJ?
QIMR-WIL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LJdmlEPTB;MkWuNVg2QCEQvF2= M3\ZO3NCVkeHUh?=
BFTC-905 M3O1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjDTWM2OD1{NT61PVQ1KM7:TR?= MXfTRW5ITVJ?
GI-1 NHvIUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ZSWlEPTB;MkWuO|A2PSEQvF2= MYrTRW5ITVJ?
MDA-MB-415 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HqeWlEPTB;Mk[uOVA{OyEQvF2= M3jXR3NCVkeHUh?=
GT3TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3noWWlEPTB;Mk[uOVM1OiEQvF2= NHLqdVNUSU6JRWK=
DEL NFPqW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ4LkizOVYh|ryP MlvTV2FPT0WU
KOSC-2 M2Prdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmcVRxUUN3ME2yOk46ODd3IN88US=> M1foWnNCVkeHUh?=
RVH-421 NUOwdnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\6TWM2OD1{Nz6yPVIyKM7:TR?= MlTBV2FPT0WU
EW-13 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjnTWM2OD1{Nz60N|A5KM7:TR?= MY\TRW5ITVJ?
639-V NWnkOYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLaTWM2OD1{Nz61NVE6KM7:TR?= MUXTRW5ITVJ?
A2780 NVfKZYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13lVGlEPTB;MkeuOlQyKM7:TR?= MULTRW5ITVJ?
SW982 NXnN[5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLkTWM2OD1{Nz65NFUzKM7:TR?= NYnJcZppW0GQR1XS
SW1710 NHfKNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hi[WlEPTB;MkiuNFk5OSEQvF2= MXHTRW5ITVJ?
HCC1569 NFjJSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ6LkS4PVch|ryP NX;VUFZFW0GQR1XS
MV-4-11 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfwfotnUUN3ME2yPE42PzN3IN88US=> M3TwPHNCVkeHUh?=
BHT-101 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGxXolKSzVyPUK4MlY2PzJizszN NHSyOGVUSU6JRWK=
Ca9-22 NYLrNIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XYd2lEPTB;MkiuO|E1KM7:TR?= NGLMbm1USU6JRWK=
HAL-01 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XYfmlEPTB;MkiuO|YyPSEQvF2= NWTPbHVOW0GQR1XS
D-263MG NYnyOHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jhWGlEPTB;MkmuN|Q1KM7:TR?= NIK4Wm1USU6JRWK=
NEC8 NF3sO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXzSlhKSzVyPUK5MlU2PDhizszN MWfTRW5ITVJ?
EKVX MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNzLkW4OFch|ryP Ml3GV2FPT0WU
EM-2 NVzNXIhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNzLk[zNFQh|ryP MVnTRW5ITVJ?
MFM-223 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LseGlEPTB;M{GuPFA6QCEQvF2= MkHqV2FPT0WU
SK-PN-DW NFvUUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXybnJKSzVyPUOyMlE1ODZizszN MYHTRW5ITVJ?
HuO9 M3jnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSyTWM2OD1|Mj61NlgzKM7:TR?= NEjZWYlUSU6JRWK=
MHH-PREB-1 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLOOZBKSzVyPUOyMlYzOzRizszN MXHTRW5ITVJ?
OVCAR-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TyVGlEPTB;M{KuPFM3OyEQvF2= MVPTRW5ITVJ?
NCI-H1648 NVzC[GpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzfmNKSzVyPUOyMlg3PTFizszN MmfPV2FPT0WU
MKN1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiyUmZKSzVyPUO0MlEyODFizszN NIXCWWJUSU6JRWK=
KYSE-450 NVzL[2VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe4eJRKSzVyPUO0MlY1PDRizszN NV6wO5RtW0GQR1XS
ES8 NGDlWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTlTWM2OD1|ND64PVc2KM7:TR?= NGnz[FlUSU6JRWK=
MS-1 NIPFcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jLWWlEPTB;M{SuPVU2PCEQvF2= MlvkV2FPT0WU
HOP-92 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH2SHA4UUN3ME2zOU46Ojd5IN88US=> NVrmOXljW0GQR1XS
SKG-IIIa NYjrbIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrCOYNwUUN3ME2zOk4zPTZzIN88US=> MUPTRW5ITVJ?
TE-11 NY\hcVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PHWGlEPTB;M{[uOVI1OyEQvF2= MWfTRW5ITVJ?
SK-NEP-1 M{PLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLqTWM2OD1|Nz62O|Q1KM7:TR?= NUPPU4J{W0GQR1XS
DB NHPadm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DSUWlEPTB;M{euPVE5PSEQvF2= NFrSe25USU6JRWK=
IA-LM NXn4Nm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i4TGlEPTB;M{iuNFI{QSEQvF2= MVTTRW5ITVJ?
COLO-829 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN6LkSxOVkh|ryP NIPMN5hUSU6JRWK=
TGBC11TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W4NWlEPTB;M{muNVQxQCEQvF2= MYHTRW5ITVJ?
CAL-51 M2fNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MontTWM2OD12MD6wOlEzKM7:TR?= NG\ONZJUSU6JRWK=
NCI-H2228 M{PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjoSJJYUUN3ME20NE4{PjZ{IN88US=> M2TzWHNCVkeHUh?=
C32 M4XtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vBXWlEPTB;NECuOFAzPCEQvF2= MXrTRW5ITVJ?
KU-19-19 M2KwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXWW4pvUUN3ME20NE44Pjh|IN88US=> NFu1VYdUSU6JRWK=
KNS-62 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\YN3BFUUN3ME20NE45OzhzIN88US=> NIL3UFVUSU6JRWK=
FADU MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrqTWM2OD12MT6yOVAzKM7:TR?= NXLZV5lZW0GQR1XS
CAL-33 NXLtO3A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD12Mj62O|Q6KM7:TR?= NFfuUVdUSU6JRWK=
CHP-134 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTR{Lki0PVYh|ryP M3SxZnNCVkeHUh?=
HDLM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tac2lEPTB;NEKuPVA5PCEQvF2= MXzTRW5ITVJ?
NBsusSR NWDld4x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR|LkC3NlUh|ryP NWX5UWRDW0GQR1XS
SW954 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTR|LkGwOVMh|ryP NFWyflVUSU6JRWK=
HCC1806 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHpTWM2OD12Mz60NVEh|ryP NFPqV5ZUSU6JRWK=
VMRC-RCZ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXVdll{UUN3ME20N{41PTh4IN88US=> NU\LdZE1W0GQR1XS
A549 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLGTWM2OD12Mz65N|Eh|ryP MVLTRW5ITVJ?
NKM-1 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3HVW1KSzVyPUSzMlk2PThizszN MWXTRW5ITVJ?
DMS-273 NUjGPY5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vHcmlEPTB;NESuO|U3PyEQvF2= M2HRV3NCVkeHUh?=
TYK-nu NY\yO5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR3LkGyN|Qh|ryP NVLlfHNqW0GQR1XS
KALS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3U2lEPTB;NEWuNVQ3KM7:TR?= NYLSZpV3W0GQR1XS
A101D M2\jWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLYT5hnUUN3ME20OU41PDV4IN88US=> M1:wOnNCVkeHUh?=
G-361 M{nDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HqNGlEPTB;NE[uNlE{QCEQvF2= NYfBU|VNW0GQR1XS
KARPAS-299 NHS4WnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXDN5BKSzVyPUS2MlM2OTZizszN M2fBXXNCVkeHUh?=
RS4-11 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne5TWM2OD12Nj61OFIh|ryP NF\5flFUSU6JRWK=
HT-1376 M1TYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPNXHdPUUN3ME20Ok44PDJ4IN88US=> M2K5[HNCVkeHUh?=
SK-N-AS Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR4Lke4NlIh|ryP NHvodItUSU6JRWK=
MG-63 M373bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR4LkmwN|Yh|ryP MoPsV2FPT0WU
EPLC-272H MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnwWHBLUUN3ME20Ok46PTB|IN88US=> NW\ubVVNW0GQR1XS
BALL-1 NEj6Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR5LkizNkDPxE1? NHvyb|NUSU6JRWK=
LCLC-97TM1 NWjhc3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLhTWM2OD12OD6yNFIh|ryP MVHTRW5ITVJ?
HO-1-N-1 M2TER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3viVWlEPTB;NEiuPVY4PiEQvF2= NGrHeWtUSU6JRWK=
MFE-280 NYnWN3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjoTWM2OD12OT60OlE4KM7:TR?= NVS2SlA3W0GQR1XS
NCI-H526 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPpdWZuUUN3ME20PU45OTZ|IN88US=> M2foTHNCVkeHUh?=
D-566MG NFzvUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTR7LkmwPVYh|ryP Mlr0V2FPT0WU
BB30-HNC MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzwWlRTUUN3ME20PU46PDl6IN88US=> M3rNN3NCVkeHUh?=
SK-N-DZ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL5TWM2OD13MD6wOFgyKM7:TR?= NF7WNZRUSU6JRWK=
HepG2  NXP0NoMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXEfJgyOMLizszN NXLuUYdGOjRiaB?= NILxOphjdG:la4OgV2MuUUmLMz3pcoR2[2WmIGOgdIhie2ViYYLy[ZN1 MmXUNlU2OjdzMkO=
HepG2  M{LLe2Z2dmO2aX;uJGF{e2G7 NEniSlAyOMLizszN MUmyOEBp MVnzeZBxemW|c3XzJJRp\SCyaH;zdIhwenmuYYTpc45{KG:oIFHUUUBwdiCVZYKxPVgyNCCFaHuxJI9vKFOnckO0OUwhS2itMjDvckBVcHJ4ODygZY5lKEOma{Kgc44hXHm{MUWgbY5lfWOnZDDifUBUSy2LSVmz NXuxd4puOjV3MkexNlM>
KATO III  M4ixb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\LemYzNjVxNT:3MlUh|ryP MWLEUXNQ MXPlcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ? MlXNNlQ5PDF5MUi=
hTCEpi NUjrbmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVryUGltOTBizszN MYXEUXNQ MojCdJJmfmWwdIOgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG:oIFjTWk0y NIHFRpEzPDN5MEizOS=>
MCF10A MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCXVExKM7:TR?= NUjWVFFoOjRiaB?= M2rlRmROW09? M4\zSJBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiR1G= NI\p[mkzPDF3MEW5OS=>
HL-60  NV24NVFkTnWwY4Tpc44hSXO|YYm= NV;lXJo5OTBizszN MVGwMlUhcA>? NU\TU5NiTE2VTx?= NEPDeFhz\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC= NILrUGYzOzl|NESxNS=>
MCF-7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkNU0yODEQvF2= MYCyOEBp MUnGRnM> Mn;RbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? M2TxelI{OTh3M{S3
HeLa  NXnVXWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpbphROS1zMEFOwG0> MnHoNlQhcA>? M4npcGZDWw>? MXLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NF;BfmgzOzF6NUO0Oy=>
SH-SY5Y MlrvSpVv[3Srb36gRZN{[Xl? NIf1RlIyOMLizszNxsA> MmDLNlQhcA>? MlnBbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? NIfZdYQzOjZ{N{K5OC=>
IMR-32 NYXjUJZQTnWwY4Tpc44hSXO|YYm= M{LCOFExyqEQvF5CpC=> NETPOJEzPCCq M2S3[YlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| NWHBWIlQOjJ4MkeyPVQ>
A549 NUH1O|BGTnWwY4Tpc44hSXO|YYm= NIm4cZEyOMLizszNxsA> MUCxJIg> M4XOTZN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= M336V|IzPTV7M{Kx
T47D  M{WxRWZ2dmO2aX;uJGF{e2G7 MVWyNOKhdU1? NGrOd20zPCCq M4TnbWROW09? MXPwdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? NYm1PWJYOjFzNES4NFU>
A29 MEF MljiSpVv[3Srb36gRZN{[Xl? NIjYR3QyOMLizszNxsA> NWHZSXR3OWh? NUO2eo1W[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? NYfVNWhFOjByNUO3PFE>
MDA-MB-453  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV61MVQxKM7:TR?= MVK3NkBp MkDrTWM2OCCxZjCxNEDPxE1? M1jwZVIxODV|N{ix
PC-3 NYezS29ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3WS4dLPS12MDFOwG0> MlzyO|IhcA>? M1\1W2lEPTBib3[gNVAh|ryP M4HQWVIxODV|N{ix

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products4

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID